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Abstract
Background: Pharmacogenomic technologies aim to redirect drug development to increase safety and efficacy of
individual care. There is much hope that their implementation in the drug development process will help respond
to population health needs, particularly in developing countries. However, there is also fear that novel
pharmacogenomic drugs will remain too costly, be designed for the needs of the wealthy nations, and so
constitute an unnecessary “luxury” for most populations. In this paper, we analyse the promise that
pharmacogenomic technologies hold for improving global public health and identify strategies and challenges
associated with their implementation.
Discussion: This paper evaluates the capacity of pharmacogenomic technologies to meet six criteria described by
the University of Toronto Joint Centre for Bioethics group: 1) impact of the technology, 2) technology
appropriateness, 3) capacity to address local burdens, 4) feasibility to be implemented in reasonable time, 5)
capacity to reduce the knowledge gap, and 6) capacity for indirect benefits. We argue that the implementation of
pharmacogenomic technologies in the drug development process can positively impact population health.
However, this positive impact depends on how and for which purposes the technologies are used. We discuss the
potential of these technologies to stimulate drug discovery in the case of rare (orphan diseases) or neglected
diseases, but also to reduce acute adverse drug reactions in infectious disease treatment and prevention, which
promises to improve global public health.
Conclusions: The implementation of pharmacogenomic technologies may lead to the development of drugs that
appear to be a “luxury” for populations in need of numerous interventions that are known to have a demonstrable
impact on population health (e.g., secure access to potable water, reduction of social inequities, health education).
However, our analysis shows that pharmacogenomic technologies do have the potential to redirect drug
development and distribution so as to improve the health of vulnerable populations. Strategies should thus be
developed to better direct their implementation towards meeting the needs and responding to the realities of
populations of the developing world (i.e., social, cultural and political acceptability, and local health burdens),
making pharmacogenomic technologies a necessary “luxury” for global public health.
Keywords: Pharmacogenomic technologies, drug development, health innovations, global, public health, develop-
ing world populations, University of Toronto Joint Centre for Bioethics criteria, inequity, luxury
Background
Luxuries are generally defined as goods that respond to
wants rather than needs, and are more often associated
with things that are frivolous rather than those that con-
stitute a necessity. An economic concept, a “luxury
good” refers to goods for which the costs, in terms of
household expenditures, rise more rapidly than income
[1]. Consequently, sports cars, expensive jewellery, spa-
cious homes and rare foods or wines are all goods that
we voluntarily classify as luxuries in richer countries.
However, defining goods as luxuries may depend in
important ways on the cultural and social realities in
which the goods are distributed. Access to certain types
of housing, food or education even at their simplest
level may, for example, constitute luxuries in the context
of low-income countries. The distribution of certain
* Correspondence: catherine.olivier@umontreal.ca
Bioethics Programs, Department of Social and Preventive Medicine,
Université de Montréal, Montréal, Canada
Olivier and Williams-Jones Globalization and Health 2011, 7:30
http://www.globalizationandhealth.com/content/7/1/30
© 2011 Olivier and Williams-Jones; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
goods in a context of significant global inequalities can
raise doubts regarding their uselessness, and thereby
change the perception of luxury or necessity in a given
context.
Healthcare services and goods are usually perceived of
as needs, and so health innovations such as genomic
technologies, which apply information obtained from
the genome (complete genetic material) of individuals or
organisms to medical innovations, often benefit from
wide public support. However, international health
inequities raise questions about the global acceptability
of many health innovations. Inequities in health are
described as inequalities that can be considered both
unjust and avoidable [2]; and they are increasingly
affecting the least favoured populations of the world.
Although discussions are still ongoing in the bioethics
literature with regards to how and why inequalities can
be declared unjust or avoidable, these inequities can
often be attributed directly to various economic, political
and social determinants. It is argued that the reduction
of health inequities may more easily result from
increased access to basic needs (e.g., food, potable water,
shelter), than from public investments in health innova-
tions that show low potential for responding to pressing
population health needs [3,4]. Thus, although a good
deal of hype surrounds the potential of emerging geno-
mic technologies to improve public health, these might
be reasonably considered a luxury for populations of the
developing world that have clearly identified and press-
ing needs for basic public health interventions.
Genomics medicine as a field of study emerged with
the sequencing of the human genome. It is considered
by many to have the potential not only to revolutionize
the way we do medicine, but also to lead to technologies
that will help reduce the significant gap in life expectan-
cies that exist amongst various populations of the world
[5]. Pharmacogenomics, which integrates genomics
information in the drug development and prescription
processes, is one example of such technologies. The
potential of genomic technologies to revolutionize medi-
cine derive from two important observations: 1) the
implementation of prior technological innovations in
medical practice have been a major contributor to the
decrease in global mortality and increase in life expec-
tancy for the period spanning 1960 to 1990 [6], and 2)
genomics knowledge can be understood as a global pub-
lic good that can have a potential positive impact at the
international level.
Global public goods are goods that are both non-
excludable (can be enjoyed by all, e.g., water) and non-
rivalrous (can be consumed by many without suffering
from depletion, e.g., air), and made public across
national borders [7]. One such public good is scientific
knowledge, and for our purposes, genomics. As
genomics research and medicine result from population-
based knowledge and applications, and because the field
has from the outset transcended national or institutional
borders (e.g., international collaborations, publishing in
scientific journals, submitting raw data to public Inter-
net databases), the “publicness” of genomics has also
shifted from a national to a global level [7]. Genomics
knowledge and resulting technologies should thus be
seen as a public good to benefit all of humanity - and
especially those populations most in need - and not sim-
ply as a luxury resource to meet the wants of popula-
tions in developed countries.
Assessing the Potential of Genomics Technologies in
Public Health
In 2002, the University of Toronto Joint Centre for
Bioethics published a study that aimed to identify the
Top 10 biotechnologies most likely to improve health in
developing countries in the next 5 to 10 years [8]. Their
study was the result of an initiative that followed the
2000 United Nations presentation of the Millennium
Development Goals (MDG), which aim to significantly
reduce poverty and improve health at the global level by
2015. The Toronto group hoped to identify technologies
associated with genomics that could contribute to global
efforts to reach the MDG. Their study provides clear
indications on the types of technologies that should ben-
efit from public investment in order to reduce global
inequities in health. These include [8]:
1. modified molecular technologies for affordable,
simple diagnosis of infectious diseases,
2. recombinant technologies to develop vaccines
against infectious diseases,
3. technologies for more efficient drug and vaccine
delivery systems,
4. technologies for environmental improvement
(sanitation, clean water, bioremediation),
5. sequencing pathogen genomes to understand their
biology and to identify new antimicrobial drugs,
6. female-controlled protection against sexually
transmitted diseases, both with and without contra-
ceptive effect,
7. bioinformatics to identify drug targets and to
examine pathogen-host interactions,
8. genetically modified crops with increased nutri-
ents to counter specific deficiencies,
9. recombinant technology to make therapeutic pro-
ducts more affordable,
10. combinatorial chemistry for drug discovery.
The Toronto study was initiated in 2001, and the 5 to
10 years period during which the technologies identified
should have an impact on population health has now
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passed. Given technological developments in the last
decade, a similar study today would probably lead to the
identification of different technologies, and include, we
suggest, pharmacogenomic technologies. Pharmacoge-
nomic technologies, which integrate genomic informa-
tion obtained following the completion of the human
genome project and other genomics initiatives (e.g., the
HapMap project) in drug development and distribution
protocols, hold the promise of reducing adverse drug
effects or reactions (ADRs) that result from genomic
polymorphisms that affect individual drug metabolism
and elimination [9]. These technologies include pharma-
cogenomic tests for predicting individual drug response
and drug testing for their genomic efficacy, leading to
the development of pharmacogenomic drugs. Their
implementation in the healthcare context promises to
increase safety and efficacy by personalising the treat-
ment of diseases and health related problems [10,11],
and much hope - and hype - has accompanied their
development [12].
At the global level, it has been suggested that pharma-
cogenomic technologies hold the potential to improve
knowledge about neglected and orphan diseases, and to
lead to the development of novel drugs that could
improve global population health [13-15]. Not surpris-
ingly, initiatives have emerged in some low or middle-
income countries (e.g., Thailand, Mexico and India) to
integrate pharmacogenomics into their efforts to meet
the MDG [16-18]. The potential of pharmacogenomic
technologies to positively impact global public health
depends on their development and application at both
national and international levels, something that necessi-
tates national and international policy-making, health
related agreements and public investment. A systematic
evaluation of the potential of these technologies is thus
needed to help identify issues and considerations sus-
ceptible to impact their effective implementation. Such
an evaluation can help determine whether pharmacoge-
nomic technologies should be seen as a “luxury” or a
“necessity” for populations of low- and middle-income
countries (can they really improve global public health?),
and thus empower local and international decision
makers to make informed choices about the funding (or
not) of pharmacogenomic innovations.
This article is the first step in a study that seeks to
evaluate the potential that pharmacogenomic technolo-
gies hold to address the needs of population health and
reduce global injustice in health through access to safe
and effective medicines. The criteria chosen for the cur-
rent evaluation are the ones initially described by the
Toronto group and the United Nations report on Geno-
mics and Global Health in 2004. They can be sum-
marised in six major points [5,8]:
1. impact of the technology (capacity for
improvement),
2. technology appropriateness (affordability, adjust-
ability to health care settings, as well as social, cul-
tural and political acceptability),
3. capacity to address local burdens,
4. feasibility to be implemented in a reasonable time,
5. capacity to reduce the knowledge gap (provide
knowledge advancement), and
6. capacity for indirect benefits (e.g., environmental
or social).
Each of these criteria will be examined in turn and
applied to pharmacogenomic technologies. This analysis
does not aim to prove that current pharmacogenomic
technologies will or can actually meet population health
needs. Instead, the aim is to provide a structured analy-
sis of the promises of pharmacogenomic technologies in
order to clarify what they would have to accomplish,
and the associated challenges, in order to contribute to
improving population health and global justice.
Discussion
The current international public health context is one
where many populations have significant problems in
accessing appropriate healthcare services and medica-
tions, thus constituting a major global injustice. This
injustice is further exacerbated by the fact that technolo-
gical and medical innovations have historically been
developed for populations of high-income countries in
the developed world, thereby contributing to disparities
in world health. This is particularly apparent in the “90/
10 gap”, where 90% of investment in drug development
is directed towards meeting the needs (or wants) of
developed world populations, while only 10% is directed
towards the needs of developing world populations
[19,20]. In 2011, the CIA World Factbook estimates a
40 year difference in the life-expectancies between the
world’s richest and poorest populations; the countries
with the highest life-expectancy are Andorra and Japan
at 82 years, while the lowest life-expectancy can be
found in Angola, at 38 years [21]. Ten countries are
listed as having a life-expectancy of 50 years or less, 9 of
which are from the African continent [21].
This population life-expectancy gap clearly demon-
strates that certain populations, but not others, have the
tools and opportunities that enable them to lead or
expect to lead longer and healthier lives. Moreover,
these disparities inequitably and unjustly affect the peo-
ples of the developing world. The root causes are
numerous and tied to national realities that make it
exceedingly difficult to address at a global level [20].
Nonetheless, there are some tools or opportunities
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developed and provided by groups or institutions with
global activities that can have an impact on local or
national public health realities. One such actor is the
pharmaceutical industry, which has benefited from the
globalization of markets and is constantly increasing
drug distribution around the globe [22]. Among the
tools developed in this industry are pharmacogenomic
technologies and drugs. But, it is not clear yet how
pharmacogenomic technologies can or will be applied in
today’s global health context. In brief, can the implemen-
tation of pharmacogenomic technologies in the drug
development process contribute to meeting the health
needs of vulnerable populations of the developing world?
In working through the Toronto group’s framework, the
present analysis evaluates the potential of pharmacoge-
nomic technologies and identifies means by which var-
ious actors in pharmacogenomics can begin addressing
pressing global public health needs.
1) Potential impact of pharmacogenomics
The idea that genetics might have an influence on indi-
vidual responses to various medications is far from new.
It was Archibald Garrold, at the beginning of the 20th
century, who first described chemical individuality in
drug response [23]. Since then, numerous examples of
varying individual responses to specific drugs have been
identified. A now classic case is Merck Frosst’s star pro-
duct Vioxx, withdrawn from the market in September
2004 following evidence of significant ADRs. This non-
steroidal anti-inflammatory drug, introduced in the late
1990s as a replacement for classic anti-inflammatory
drugs such as ibuprofen, is part of the Cox-2 inhibitor
family which has since been shown to have variable
effects on the cardiovascular system and blood pressure,
notably increasing the risk of heart attacks and strokes
in some individuals [24,25].
Diversity in drug reaction due to genetic differences is
a major factor in ADRs, in combination with physiologi-
cal (weight, gender and age), environmental (pollution
and diet) and social (wealth, education and family) fac-
tors that are susceptible to impair treatment success and
that can even lead to death [26]. The relative efficiency
of a specific drug or treatment commonly used in hospi-
tals has been shown to vary between 30 and 70% [27]. A
milestone publication on the topic demonstrated that in
the United States alone, there are approximately 2 mil-
lion hospitalisations and 100,000 deaths per year attribu-
table to ADRs [28]. A more recent meta-analysis
suggests that ADRs account for approximately 5% of
hospital admissions in Western countries [29], with
higher rates among the elderly (up to 16.6%) [30]. Inter-
estingly, a 2005 study of emergency department admis-
sions in India found that between 6 and 7% of
admissions were due to ADRs, and that in most cases
(60%) these were avoidable [31]. These studies show
that the occurrence of ADRs constitutes a significant
population health problem worldwide.
In the US, close to 50% of the population uses at least
one prescription drug on a regular basis; the most com-
mon drugs are for treating asthma in children, and anti-
depressants and cholesterol lowering drugs [32]. In the
developing world, prescription drug sales have been on
the rise and IMS Health (Intercontinental Medical Sta-
tistics) estimates that the $67 billion in sales in 2003
will jump to a staggering $265 billion by 2013 [33].
Pharmaceutical companies such as Pfizer or Novartis
are building on the promise of market expansion and
have a growing number of sales representatives market-
ing their star products, such as Lipitor, to doctors and
clinics in low-income countries [33]. Considering the
importance that prescription drugs play in modern med-
ical and public health practices, tools to enable more
effective evaluations of the safety and efficacy of a drug
in a particular population, or for specific individuals, in
order to reduce the occurrence of ADRs could have an
important positive impact on global public health.
In taking into account the genetic factors susceptible
to influence the metabolic outcome of specific drugs for
individuals or for segments of the population, pharma-
cogenomics promises to contribute to better success in
disease treatment and an increase in the general health
of the population [34]. For example, the integration of
genomic information relating to drug metabolism during
the drug development process will hopefully enable the
pharmaceutical industry to develop drugs better suited
for the treatment of diseases in particular ethnic groups
or for a portion of the population sharing similar geno-
mic characteristics. Moreover, a shift towards the devel-
opment of pharmacogenomic drugs may justify focusing
research and development efforts on diseases or biologi-
cal susceptibilities (ADRs, response to pathogens or pre-
dispositions to diseases) that are characteristic of
specific populations. This can be extremely important
for populations disfavoured by the current 90/10 context
in drug development, namely the populations of low and
middle-income countries.
The implementation of pharmacogenomic technolo-
gies in the drug development and distribution context
could thus have a positive impact on population health.
But these technologies may also raise serious ethical
concerns in other spheres of society (e.g., social, cultural
or political) that could undermine the appropriateness
of these technologies.
2) Appropriateness of pharmacogenomic technologies
The second criteria used by the University of Toronto
Joint Centre for Bioethics study for the evaluation of
novel technologies most susceptible to impact health in
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developing world countries is the technology’s appropri-
ateness [8]. Daar and colleagues describe this criterion
in relation to the technology’s affordability, robustness,
adjustability to the local contexts and social, cultural or
political acceptability.
Affordability
Affordability is clearly a major concern in a developing
world context. But it is not sufficient to say that “the
drugs are too expensive"; drug costs, and thus their
affordability, are associated both with the social cost of
investing in these technologies (upstream innovation)
and the resulting (downstream) cost of then integrating
these technologies in the drug development and distri-
bution process. One third of the world’s population cur-
rently does not have access to basic essential medicines
[35], and this proportion extends to half the population
in the poorest regions of the globe (e.g., certain regions
in Africa and Asia). Not surprisingly, then, drug accessi-
bility constitutes an important element in preoccupa-
tions about global justice [20]. Drug inaccessibility is in
large part due to the fact that many drugs are simply
too costly for people to purchase, especially those living
in low- or middle-income countries that invariably lack
universal healthcare insurance programs.
This situation is exacerbated by the defence - on the
part of the pharmaceutical industry and governments of
developed countries - of strong intellectual property
rights (IPRs), i.e., patents. IPRs are presented as an
essential constituent in the drug development process, a
means for companies to protect (and recoup) their eco-
nomic investment in an innovation (e.g., a drug),
thereby making it worthwhile for pharmaceutical com-
panies to invest in research and development of new
drugs. The broad and international application of strong
IPRs for medicines followed the 1995 Trade Related
Aspects of Intellectual Property Rights agreement
(TRIPS) of the World Trade Organization (WTO) [36].
These strong IPRs combined with pricing practices
designed for the wealthy developed countries can have a
significant negative impact on drug distribution, making
novel and effective drugs simply unaffordable and thus
inaccessible for people in the world’s poorest countries.
Similarly, the ways that pharmaceutical drugs are
regulated in different national contexts can have impor-
tant repercussions on the accessibility and affordability
of novel drugs for populations in need [37,38]. The lack
of regulations on the pricing or reimbursement of drugs
made expensive by the implementation of novel phar-
macogenomic technologies in their development process
can limit the potential use of these new drugs in low
and middle-income countries. The development of new
technologies, such as pharmacogenomics, often requires
sophisticated equipment, infrastructure and specialised
human resources. Unfortunately, high tech equipment
and knowledgeable human resources are two elements
that can be very costly for research groups and compa-
nies interested in investing in pharmacogenomic tech-
nologies. This situation increases the incentives for
pharmaceutical companies to raise the costs of drugs
produced using such novel technologies in order to off-
set their initial investment. When combined, these costs
constitute a significant barrier to the provision of phar-
macogenomic drugs in the developing world.
The lack of comprehensive and universal public health
insurance in most developing world countries means
that these populations bear the financial burden of ill
health. Out-of-pocket health expenditures are situated at
around 50% in low-income countries [39], among which
the greatest part is directed towards drug purchases (e.
g., 70% in India [40] and over 80% in certain Sub-
Saharan countries). These purchases constitute the sec-
ond most important household expenditure, after food
[41,42]. For example, the mean direct costs of the three
major diseases affecting populations of the developing
world (malaria, tuberculosis and HIV/AIDS) represent
between 2.5 and 7% of household income [43]. Further-
more, self-medication and over-the-counter drug pur-
chases are extremely frequent, increasing the
pharmaceutical drug share of household expenditures
[44]. Thus, even though funding of health sectors has
increased 88% between 1995 and 2006 in most develop-
ing nations (excluding Sub-Saharan Africa) [45], the
financial burdens of meeting individual health needs
inevitably reduces health benefits for these vulnerable
populations. Increasing the financial burden of drugs for
individuals (who are paying out-of-pocket) or govern-
ment organizations (e.g., public health programs) with
limited funds could be an important disincentive for
doctors and pharmacists to prescribe or sell novel drugs,
because these prescriptions would not be filled nor their
costs reimbursed by state health agencies. As a result,
novel medicines would prove to be unaffordable and
thus inaccessible for the populations of low and middle-
income countries, thereby limiting the potential benefits
of pharmacogenomic technologies for these populations.
Robustness
Robustness is a concept linked to the capacity of a sys-
tem to survive or resist unpredictable perturbations. It is
a difficult concept to assess at the social level, but can
be evaluated through the identification of variables that
may affect its vulnerability within a given setting (e.g.,
healthcare services) [46]. When it comes to implement-
ing novel technologies in healthcare services, many vari-
ables can affect long term efficiency and thus impair
robustness. Among these variables, funding availability
and allocation are significant factors since they can dic-
tate priorities and shape the direction of technological
development, elements that impact the eventual
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sustainability and success of a given technology, and
thus its robustness. Insufficient funding for drug
research and development (R&D) can, for example,
make it more difficult to develop novel drugs that can
better meet population health needs.
Funds devoted to drug R&D take a variety of forms,
the principal ones being: public funds, philanthropic
donations, government investment or tax deductions
[47]. To increase access to drugs for their populations,
certain low- (e.g., Kenya) and middle-income countries
(e.g. India, Thailand, Brazil and South Africa) have
invested in the establishment of national pharmaceutical
industries [48]. These local pharmaceutical companies
invariably focus on producing cheaper generic drugs for
their populations, but are also involved in developing
new drugs. Indian companies, for example, account for
2% of drug patents awarded in the US and almost 2% in
Europe [49].
Although pharmaceutical companies around the world
have benefited from a range of funding sources, includ-
ing government agencies promoting public health
oriented R&D agendas, actual investment in R&D
geared at meeting the needs of low- and middle-income
country populations has not risen significantly [47]. In
India, the proportion of funds allocated for R&D for dis-
eases predominant in the developing world has actually
dropped from 16% in 1998 to 10% in 2003 [49]. The
appeal of greater sales and profit in high-income coun-
tries may thus divert drug developers’ intentions to
respond to the needs of poorer populations. Finally,
political and economic pressures, such as the global
financial crisis that weakened national economies in
Europe and North America since 2008, may also contri-
bute to a decrease in funds available from national gov-
ernments and donors for drug R&D.
There are not many indications that the implementa-
tion of pharmacogenomics in the drug development
process will change the current trend in R&D funding
or orientation. Higher costs associated with their devel-
opment, as described in the previous section, may signif-
icantly impair their long term use and thus reduce their
overall robustness.
Adjustability to local contexts
The current drug R&D context already strongly disfa-
vours developing world populations. A study of the
number of publications found in the major scientific
journals (via Medline) demonstrates that this situation is
not changing; in 2004 only 1.25% of published clinical
studies related to tropical diseases [49]. It has been pro-
posed, however, that pharmacogenomic technologies
may help reduce both the cost and time needed for
drug development and maximize drug potential through
reattribution of medical purpose for previously rejected
drugs [50]. Thus, it is not obvious that these novel
technologies will necessarily increase the market cost for
novel drugs. As already mentioned, these promises have
led some authors to argue that pharmacogenomic tech-
nologies can contribute to the reduction of global health
inequities [15,51,52].
Pharmacogenomic technologies have the potential to
help scientists identify individuals likely to respond posi-
tively to a given class of drugs. This capacity can enable
researchers to better circumscribe the sample population
used for clinical testing, thereby reducing sample sizes
and better adjusting the study to local contexts. It also
reduces the period of time during which clinical tests
need to be conducted by ensuring better response possi-
bilities in the sample population. Indeed, the possibility
of screening participants for certain genomic predisposi-
tions to drug response (e.g., testing for specific major
drug metabolism enzyme alleles) could provide compa-
nies better chances of obtaining a positive response in
the majority of individuals during clinical trials. Such
positive responses would then 1) reduce the number of
trials needed to support the potential benefit of tested
drugs, 2) reduce the amount of time required for these
clinical trials, 3) facilitate the accreditation of new drugs
by national review agencies such as the US Food and
Drug Administration (FDA), and ultimately 4) help
reduce the cost of drug development and thus the over-
all price of drugs on the market [53].
However, the conduct of clinical drug trials in devel-
oping countries raises a host of ethical and practical
challenges, and pharmacogenomics research would likely
be no different. Notable concerns include: the ability to
obtain valid informed consent [54,55]; the exploitation
of vulnerable individuals who bear the risks and burdens
of research while being unlikely to benefit from the
results [56,57]; the scientific validity of clinical studies
conducted in contexts that lack appropriate regulation
and governance mechanisms [58]; and the respect of the
research participant’s right to withdraw from clinical
trials [59].
Finally, the integration of pharmacogenomic informa-
tion in the context of clinical trials could be used to
unfairly exclude groups of individuals with greater risks
of developing ADRs to the drug being tested. On the
one hand, severe ADRs in individuals may not be
assessed in clinical trials that preselect participants
based on their potential to respond positively to a given
drug. Alternative drug development may be abandoned
for the least interesting vulnerable groups of individuals
that prove at higher risk of ADRs for the major drug
being developed. Pharmaceutical companies could thus
use this information to take important decisions on the
withdrawal from the development pipeline of drugs that
are shown to have limited market potential (the popula-
tion who would benefit is too small, too poor, etc.),
Olivier and Williams-Jones Globalization and Health 2011, 7:30
http://www.globalizationandhealth.com/content/7/1/30
Page 6 of 13
even though these could prove to be safer and more
efficient for the vulnerable populations of low and mid-
dle-income countries.
Social, cultural or political acceptability
The development of drugs that are better suited to the
local context in terms of population and cost can
increase the possibility for populations of developing
countries and their governments to purchase much
needed drugs. The implementation of pharmacogenomic
technologies in the drug development and distribution
context can in this sense be considered socially and
politically acceptable; however, it is not obvious that the
implementation of such technologies will necessarily
respond to norms of cultural acceptability.
The first drug labelled for a racially identified popula-
tion was BiDil, approved in 2005 by the FDA for treat-
ment of chronic heart failure in individuals of African-
American origin [60]. This drug was shown to reduce
mortality by 43% and hospitalisations by 39% in Afri-
can-Americans, but showed no specific increase in effi-
ciency for other racial groups [61]. At first glance, the
development of a drug that is specific to a particular
ethnic or racial group, and which addresses an impor-
tant health need, is a perfect example of progress
towards developing personalised medicines that meet
the needs of specific communities, and not only the
general population. However, important critiques have
been raised about the BiDil study’s validity (e.g., regard-
ing participant selection procedures) [62-64], and its dis-
tribution in a race-based manner [65-67]. Notably, the
high cost of BiDil raises questions about the utility of
developing drugs based on race or ethnicity that may
provide more personalised treatment to individuals, but
prove to be inaccessible to those populations most in
need [68].
The BiDil case also highlights more general concerns
about ethno-typing in pharmacogenomics studies. In
focusing on rough ethnic or racial categories (instead of
more neutral genomic or biomarker categories), studies
in pharmacogenomics may lead to undue and incorrectly
linear associations of specific genetic dysfunctions with
ethnic groups, thereby contributing to or augmenting
pre-existing racial discrimination and ethnic stigmatiza-
tion. Furthermore, instead of using pharmacogenomic
information on a vulnerable population to direct drug
development to meet their specific needs, such informa-
tion can be used as a population exclusion criteria. That
is, companies or governments might want to exclude cer-
tain populations from studies because they are vulnerable
(i.e., are socially or politically sensitive) and not suffi-
ciently wealthy to afford the resulting product.
It is also important to consider social and cultural fac-
tors related to the perception of Western medicines in
comparison with traditional forms of medicine.
Specifically, people may have very different views -
informed by religious/spiritual, cultural or social factors
- regarding the utility and function of pharmaceutical
drugs [69], who should prescribe them [70], who they
are appropriate for, and how they should be used
[71,72]. Such factors will likely have an impact both on
participation in clinical trials of pharmacogenomic tech-
nologies, and in the uptake of any resulting pharmaco-
genomic drugs. Further, in contexts where there is little
or no universal drug insurance - the case for most low-
and middle-income countries - individual consumers
will often be the final decision maker (purchasing the
drug from a pharmacist or street vendor) about which
drug is appropriate for them and their families, regard-
less of the actual clinical indication of pharmacogenomic
specificity.
Possible racial discrimination and stigmatization in the
drug development and distribution process, along with
important variation in how peoples perceive novel Wes-
tern medicines, place pharmacogenomics in an ambigu-
ous situation with regards to the ability to address
inequities in global health. The benefits gained from the
integration of pharmacogenomic technologies into medi-
cal practices might thus be accompanied by significant
social disadvantages that actually impair the capacity of
these technologies to address local health burdens.
Companies and governments investing in pharmacoge-
nomics must therefore pay careful attention to both the
needs and the socio-cultural contexts of the populations
that they are seeking to help.
3) Capacity to address local burdens
Pharmacogenomic technologies may provide powerful
tools to enable the pharmaceutical industry to develop
drugs that are specific for diseases that afflict the devel-
oping world population, promising important modifica-
tions to the current drug development and distribution
system. In targeting sub-groups or populations, these
technologies have the potential to fragment the market
for innovative drugs (many sub-populations, many com-
peting drugs) and so force pharmaceutical companies to
move away from their traditional blockbuster (1 disease
= 1 drug) model [52]. It is thus not clear that these
technologies will favour a change in the current philoso-
phy of drug discovery that is focused on meeting the
demands of wealthy countries.
The development of a multiplicity of pharmaceutical
drugs that can respond to novel disease niches could
help compensate for this market segmentation, creating
new market opportunities for the various actors in drug
development and distribution [52]. Obviously such seg-
mentation does not guarantee that drug development
will be geared towards meeting the needs of developing
country populations. However, it may make smaller or
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less profitable markets, such as low and middle-income
countries, more attractive for drug developers [52]. This
is especially true when population size is taken into con-
sideration, since low- and middle-income countries
account for most of the world population. Segments or
sub-groups of the population in these contexts have the
potential to be greater in number than in developed
countries and so can represent more interesting market
shares. Nonetheless, pricing models (drugs priced for
developed world markets) would also need to change
for the benefits associated with market segmentation to
be actualised. In reality, introducing pharmacogenomic
technologies into drug R&D processes may increase the
cost (and thus market price) for novel drugs and lead
some pharmaceutical companies to choose not to invest
in sectors with less attractive market potential, namely,
lower cost drugs addressing the needs of developing
world populations. Pharmacogenomic drugs will thus
become costly “luxuries”, only available to wealthy mem-
bers of genomic sub-populations, thereby contributing
to a widening of the already significant global gap in
access to safe and effective medicines.
The ongoing HIV/AIDS epidemic and access to anti-
retroviral therapy (ART) is one example of the current
challenges in making safe and effective medicines accessi-
ble. The highest HIV prevalence in the world is in devel-
oping countries, with 68% of HIV-infected individuals in
the Sub-Saharan region [73]. ARTs are currently the
most effective means of treating HIV-infected individuals,
but they are very expensive and so unaffordable for most.
Regional governments and non-governmental organisa-
tions (NGOs) in a number of countries (e.g., Uganda,
Brazil, Thailand) have established universal drug plans
for ART. Unfortunately, a great deal of stigmatization
and discrimination is still associated with HIV+ status,
which negatively impacts compliance with ART protocols
and thus limits efforts to contain the epidemic.
It is also well documented that ARTs induce impor-
tant ADRs in certain individuals, ranging from coeta-
neous reactions (rash) to severe gastrointestinal or liver
reactions [74]. As a consequence, 25% of patients do not
adhere completely to their treatment plan, increasing
risks of HIV transmission in the general population [74].
These variations in individual response to ART are
increasingly recognised as being associated with genetic
factors [75]. As such, pharmacogenomic technologies
could help public health professionals better target spe-
cific HIV treatments for infected individuals, and also
facilitate the development of drugs that are better suited
to sub-populations based on their shared genomic back-
ground. Pharmacogenomic technologies could then
improve patient experiences and thus compliance with
ART, and compliment social and cultural efforts to
reduce stigmatisation of HIV+ individuals.
As suggested in the previous section, reductions in the
costs of drug R&D could constitute an important incen-
tive for companies to invest in pharmacogenomics
research that targets diseases that are predominant in
the developing world but costly to treat (such as HIV),
as well as those that have not yet been well explored (e.
g., orphan or neglected diseases). For example, it has
been suggested that pharmacogenomics could be used
in drug response predictions for treatments for Crohn’s
disease [76]. Crohn’s disease is a disorder characterized
by lifelong inflammation of the intestinal muccosae for
which no cure presently exists, and is sometimes classi-
fied as a rare disease (e.g. Orphanet database on rare
diseases and orphan drugs [77]). In the US, the preva-
lence of Crohn’s disease is estimated to be approxi-
mately 500,000 individuals. This prevalence excludes it
from the classical definition, which defines an “orphan
disease” as a disease affecting less than 200,000 indivi-
duals. Crohn’s is nonetheless not a very common dis-
ease. Regular treatment of individuals with Crohn’s
disease includes the use of Tumor necrosis factor-a
(TNF-a) inhibitors, such as Infliximab (Remicade®).
However, infusion of this monoclonal antibody induces
remission in only 30-40% of cases. Two polymorphisms
have been identified on the TNF-a receptor that are
associated with drug response, making pharmacoge-
nomic technologies useful in the prediction of treatment
efficacy in Crohn’s disease patients [76], and in directing
drug development.
The development of new drugs targeting diseases that
affect less fortunate populations may not be considered
profitable for the pharmaceutical companies of develop-
ing countries, many of which are still struggling to move
beyond the traditional blockbuster model that focuses
on the diseases of the rich. The potential of pharmaco-
genomic technologies to change the research focus of
pharmaceutical companies towards the diseases predo-
minant in the developing world is not obvious in the
current context.
4) Feasibility and timeliness of implementation
One major limitation of emerging technologies is their
successful implementation. To evaluate this factor, the
Toronto group proposed that these technologies should
have an impact on the health of developing world popu-
lations in a reasonable time frame (i.e., 5 to 10 years).
The health needs of developing world populations are
great, and so technologies should be evaluated (and
prioritised) based on their potential for timely
implementation.
A number of pharmacogenomic drugs (e.g., Herceptin,
Gleevec, Velcade or Erbitux) and drug sensitivity tests
(e.g., for abacavir, tamoxifen or warfarin) have been
developed. Nonetheless, the relative success of
Olivier and Williams-Jones Globalization and Health 2011, 7:30
http://www.globalizationandhealth.com/content/7/1/30
Page 8 of 13
pharmacogenomics technology implementation in the
drug development and distribution process is still lim-
ited [78]. The low level of development of these technol-
ogies is even more evident when attention is focused on
the needs of developing world populations. Only one of
the 14 drugs approved by the FDA for which pharmaco-
genomics data are available - i.e., abacavir, a treatment
for HIV+ patients - is geared specifically towards meet-
ing the needs of populations in the developing world.
There has been little success (or interest?) in gathering
relevant pharmacogenomic information on drugs pre-
sently in use. Some progress appears to be happening
with cancer treatments, with 7 of the 14 drugs for
which pharmacogenomic tests are available being geared
towards cancer; but the same cannot be said for diseases
prevalent in the developing world.
The translation of scientific research into drug discov-
ery and development is a process that can take between
5 to 10 years. Pharmacogenomic technologies are for
the most part still in the early stages of development, so
it is possible that their successful implementation in
drug development is not yet feasible, nor easy to mea-
sure accurately. An interim evaluation may be possible,
however, by examining the place of pharmacogenomics
science in the global health research context. For exam-
ple, qualitative and quantitative data on the amount and
type of research being done using pharmacogenomic
technologies (e.g., through an analysis of scientific publi-
cations) could provide some indication of whether phar-
macogenomics research is actually targeting the needs
(e.g., diseases) of developing world populations. The cur-
rent reality, however, is that pharmacogenomic technol-
ogies have not yet met the requirement for successful
implementation in a reasonable time frame as proposed
by the Toronto group.
5) Capacity to reduce the knowledge gap (provide
knowledge advancement)
Pharmacogenomic information, especially about popula-
tion variations in genomic polymorphisms that relate to
drug metabolism, may allow for the rapid and efficient
screening of a variety of drugs that are in use or in
development, in order to identify the best correspon-
dence between treatment, disease and population. The
international HapMap consortium sought to develop
such information for four populations of African, Asian
and European ancestry [79]. More than 4 million single
nucleotide polymorphisms (SNPs) were initially identi-
fied, providing valuable information for gene expression
variation and pharmacogenomic studies [60,80]. How-
ever, these SNPs were mostly from people of Caucasian
descent, which created a genomics knowledge gap in the
translation of this science at a global level [81]. Phase 3
of the project was thus extended to include 11 global
populations (International Hap Map Consortium 2010),
and 26 million SNPs have now been genotyped, thereby
allowing genomic studies in peoples from diverse ethnic
backgrounds [81-84].
The information provided remains sparse, with a little
over 1000 individuals having had their DNA genotyped
during the project. It is thus still very difficult to extrapo-
late from these small samples to full populations, or to
translate the scientific knowledge into clinically applic-
able information. Other initiatives, such as the 1000 Gen-
ome Project (to genotype the full genome of over a 1000
individuals worldwide) can contribute to gathering more
of this valuable genomic information [85]. Nonetheless,
the high costs and technological requirements associated
with these projects suggest that research centres based in
developing countries may not easily contribute to nor
benefit from the information obtained. Three upper mid-
dle-income countries - Brazil, South Africa and Mexico -
and two lower middle-income countries - India and
Thailand - have developed a research framework that
allows the integration of genomic technologies into their
national scientific research settings [16,18,86,87]; such
infrastructure and human resources are simply not pre-
sent in low-income countries. This situation introduces a
technological gap between scientists from the developed
and developing worlds and is likely to reduce the amount
of information gathered concerning the populations of
these latter countries.
The creation of a knowledge gap in genomics research
capacity can translate into asymmetrical pharmacoge-
nomics drug R&D that favours those populations for
which more data are available. The geographic locations
in which pharmacogenomics research centres operate
thus becomes an important factor in defining the popu-
lations that will benefit from discoveries in pharmacoge-
nomics. The impact that genomics knowledge can have
on public health depends to a large extent on how and
why this information influences drug R&D. The use of
genomic information on the vulnerability of a popula-
tion to an HIV treatment, for example, may be very
beneficial if it encourages the development of alternate
treatments that are safer and more effective for a given
population. However, the same information could nega-
tively impact public health if it were used to reduce
treatment opportunities, for example, where novel treat-
ments are developed only for populations that show cer-
tain genomic characteristics. To cite an old adage,
“knowledge is power”, and in the case of pharmacoge-
nomics, much will depend on what knowledge is col-
lected and who has the power to put it to use.
6) Capacity for indirect benefits
Direct benefits of developing and distributing novel
pharmacogenomic drugs that better respond to the
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needs and realities of developing world populations can
be easily identified; amongst these are the recognition of
specific health needs, faster and safer access to new
drugs [88], increased population health [89], reductions
in social and global health inequities known to impair
individual health opportunities [90-93], and increased
market or work opportunities for secondary actors in
the drug distribution context (e.g., grocery stores, mar-
ket stalls, itinerant hawkers or mobile vendors [94]). All
these benefits can positively impact local population
health, which would undoubtedly be positive for global
public health. However, the possibilities that the costs of
healthcare provision may increase due to the introduc-
tion of pharmacogenomic technologies in the drug
development process could counterbalance the pre-
viously mentioned benefits. It thus becomes important
to evaluate the indirect benefits that could follow from
the implementation of pharmacogenomic technologies
in the drug development process, in order to better
assess their potential in global health.
Two potential indirect benefits are worth considering:
1) the building of a sense of “worthiness” in vulnerable
populations, and 2) economic growth for the developing
world. The recognition of the specific health needs of
populations of low- and middle-income countries by dif-
ferent health actors through the implementation of
innovative pharmacogenomic technologies can support a
growing sense of worthiness for these populations.
Indeed, vulnerable populations (e.g., elderly populations
or minorities) can build a collective sentiment of self-
esteem when their needs are recognised and addressed
[95,96]. This increased self-esteem at the collective level
helps build a sense of worthiness and identity in a popu-
lation that can have significant social impact, such as a
reduction in violence [97]. In the context of low or mid-
dle-income countries where conflicts often occur, a
reduction of violence can be significantly important to
increasing the security of the population and enhancing
population health. For example, it has been shown that
conflict increases the risk of HIV in vulnerable popula-
tions, thereby impairing population health in these
nations [98]. Conversely, the isolation and rejection that
individuals feel in the HIV epidemic increases the level
of violence and the risk of conflicts in high prevalence
nations [99]. So innovations that indirectly help building
a greater sense of worthiness in vulnerable populations,
and thus reduce violence and risk of conflict, can contri-
bute to improving global public health.
Furthermore, the social burden that accompanies poor
population health can have a significant negative impact
on the economy and development of low- and middle-
income nations. Poor health can reduce life opportu-
nities for individuals, thereby perpetuating situations of
poverty in populations that are already facing limited
resources and are in dire need of basic goods such as
food, education, shelter and healthcare services [92,93].
At the population level, the collective reductions in indi-
vidual opportunities translate into a reduced potential
for economic development for national governments,
because these reduced opportunities significantly
decrease the size of the active/working population in
these nations.
For example, diseases such as HIV or malaria in sub-
Saharan Africa disproportionately affect young adults,
are directly linked to and reinforce poverty, and so
reduce a nation’s competitiveness at the international
level [100]. Of the 13 countries with the lowest life
expectancy predictions for 2011, 10 have a per capita
GDP under $1000 [21,101,102]. Thus the burden of a
weak national economy and poor health outcomes seem
to correlate directly. There are numerous ways in which
these factors can affect one another, and so improve-
ments in population well-being can thus come from
initiatives at either or both levels. The development of
drugs that can increase the potential for better health or
better response to treatments in the population, and
thus contribute indirectly to the stabilization of the
human capital of a nation, then become a social neces-
sity. In this view, drugs that may at first appear to con-
stitute a luxury (e.g., pharmacogenomic drugs) may
actually be a necessity.
Conclusions
The current economic world order is based on princi-
ples of globalization that have made it possible for phar-
maceutical companies and their shareholders to become
extremely prosperous [22]. Pharmaceutical companies
engage in drug development in order to both address
the health needs of populations, and to contribute to
economic well being through wealth creation; and as a
result of current drug marketing models (i.e., strong
IPR, high priced drugs), the needs of people in devel-
oped countries are invariably favoured over those in
developing countries. In this context, it remains unclear
whether pharmacogenomic technologies can be put at
the service of developing world populations to enable
more equitable development of drugs that are oriented
to meeting the health needs of these neglected
populations.
Our application of the University of Toronto Joint
Centre for Bioethics criteria (i.e., impact, appropriate-
ness, capacity to address local burdens, implementation
in a reasonable time, capacity to reduce the knowledge
gap, and capacity for indirect benefits) shows, we argue,
that pharmacogenomic technologies have the potential
to make a significant positive impact on the population
health of developing world countries. But in order for
this potential to be actualised, the implementation of
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these technologies in the particular healthcare contexts
of developing countries must be carefully scrutinized.
There must be further investigation of the questions
how, where, and for which purpose are pharmacoge-
nomic technologies being developed? Answering these
questions would allow for the identification of activities
in pharmacogenomics R&D that show real promise, and
so should be favoured (e.g., through technical and finan-
cial support) in order to maximise the potential positive
impact on the health of low- and middle-income coun-
tries. It may also provide crucial information on the
responsibilities of the various actors involved in the
implementation of pharmacogenomic technologies
aimed at meeting the needs of developing world
populations.
Pharmacogenomic technologies can contribute to
shifting the pharmaceutical industry from its tradi-
tional blockbuster model of drug development towards
a more personalised and preventive approach. These
companies have international activities and so are not
limited by national boundaries, policies or realities; as
such, they have the potential to make important con-
tributions to improving global population health and
ensuring justice in access to needed healthcare ser-
vices. But given the complexity of genomic information
and the still early stage of development of most phar-
macogenomic technologies, caution is needed when
considering how best to integrate these technologies
into the drug development process to ensure that
existing social inequities are not exacerbated. In some
cases, pharmacogenomic drugs may be a “luxury” given
other pressing health needs and the existence of more
proven and effective public health interventions. But it
is in the development of drugs that are better suited to
the specific needs and realities of developing world
populations that we see that pharmacogenomic tech-
nologies can, in some cases, be considered a necessary
“luxury” in global public health.
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